利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.031 秒)

    Endothelial cell expression patterns
    2.
    发明授权
    Endothelial cell expression patterns 有权

    公开(公告)号：US07402660B2

    公开(公告)日：2008-07-22

    申请号：US09918715

    申请日：2001-08-01

    申请人： Brad St. Croix ,  Bert Vogelstein ,  Kenneth W. Kinzler

    发明人： Brad St. Croix ,  Bert Vogelstein ,  Kenneth W. Kinzler

    IPC分类号： C07K16/00

    CPC分类号： C07K16/30 ,  A61K2039/505

    摘要： To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

    Secreted and cytoplasmic tumor endothelial markers
    3.
    发明申请
    Secreted and cytoplasmic tumor endothelial markers 审中-公开

    公开(公告)号：US20060210975A1

    公开(公告)日：2006-09-21

    申请号：US10519805

    申请日：2003-07-02

    申请人： Brad St Croix ,  Kenneth Kinzler ,  Bert Vogelstein

    发明人： Brad St Croix ,  Kenneth Kinzler ,  Bert Vogelstein

    IPC分类号： C12Q1/68 ,  G01N33/567 ,  A61K48/00 ,  A61K38/17

    CPC分类号： G01N33/56966 ,  G01N33/574

    摘要： To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.

    Secreted and cytoplasmic tumor endothelial markers
    4.
    发明申请
    Secreted and cytoplasmic tumor endothelial markers 审中-公开
    分泌和细胞质肿瘤内皮标志物

    公开(公告)号：US20090233270A9

    公开(公告)日：2009-09-17

    申请号：US10519805

    申请日：2003-07-02

    申请人： Brad St. Croix ,  Kenneth Kinzler ,  Bert Vogelstein

    发明人： Brad St. Croix ,  Kenneth Kinzler ,  Bert Vogelstein

    IPC分类号： C12Q1/68 ,  G01N33/567 ,  A61K48/00 ,  A61K38/17

    CPC分类号： G01N33/56966 ,  G01N33/574

    摘要： To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.

    摘要翻译： 为了更好地了解肿瘤血管生成，开发了分离内皮细胞（ECs）和评估基因表达模式的新技术。 将来自正常和恶性结肠直肠组织的ECs的转录物与来自非内皮细胞的转录物进行比较，鉴定了主要在内皮中表达的170个以上的基因。 正常和肿瘤衍生的内皮的比较显示许多差异表达的基因，包括在肿瘤相关内皮中特异性升高的大量的基因。 来自该组的代表性基因的实验证明，大多数类似地在原发性肺，乳腺，脑和胰腺癌的内皮以及肝脏的转移性损伤中表达。 这些结果表明，人类的肿瘤和正常内皮在分子水平上是不同的，对抗血管生成的发展具有重要意义。

    Endothelial cell expression patterns
    5.
    发明授权
    Endothelial cell expression patterns 有权

    公开(公告)号：US07358351B2

    公开(公告)日：2008-04-15

    申请号：US10979159

    申请日：2004-11-03

    申请人： Brad St. Croix ,  Bert Vogelstein ,  Kenneth W. Kinzler

    发明人： Brad St. Croix ,  Bert Vogelstein ,  Kenneth W. Kinzler

    IPC分类号： C07H21/04 ,  C12P19/34

    CPC分类号： C07K16/30 ,  A61K2039/505

    摘要： To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

    DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS
    9.
    发明申请
    DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS 有权
    生理和病理生物学中的差异基因表达

    公开(公告)号：US20110207141A1

    公开(公告)日：2011-08-25

    申请号：US13052878

    申请日：2011-03-21

    申请人： Brad St. Croix ,  Steven Seaman

    发明人： Brad St. Croix ,  Steven Seaman

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： C12Q1/6886 ,  A61K39/39558 ,  A61K45/06 ,  C12N15/1072 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57492 ,  G01N33/57496 ,  G01N33/6893

    摘要： Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.

    摘要翻译： 公开了抑制受试者病理血管发生的方法。 在具体实例中，该方法包括向受试者施用治疗有效量的组合物，其中组合物包含优先结合一种或多种病理性血管发生标志物蛋白的特异性结合剂，包括Vscp，CD276，ETSvg4（Pea3），CD137（4 -1BB），MiRP2，泛素D（Fat10），Doppel（朊病毒-PPL），Apelin，Plgf，Ptprn（IA-2），CD109，强直性骨髓和胶原VIIIα1。 在另外的实施例中，还公开了将治疗剂递送至脑或肝内皮细胞的方法。

    DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS
    10.
    发明申请
    DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS 审中-公开
    生理和病理生物学中的差异基因表达

    公开(公告)号：US20100028256A1

    公开(公告)日：2010-02-04

    申请号：US12514297

    申请日：2007-06-28

    申请人： Brad St. Croix ,  Steven Seaman

    发明人： Brad St. Croix ,  Steven Seaman

    IPC分类号： A61K51/00 ,  A61K39/395 ,  C12Q1/68 ,  G01N33/53 ,  C12N5/02 ,  A61P35/04

    CPC分类号： C12Q1/6886 ,  A61K39/39558 ,  A61K45/06 ,  C12N15/1072 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57492 ,  G01N33/57496 ,  G01N33/6893

    摘要： Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.

    摘要翻译： 公开了抑制受试者病理血管发生的方法。 在具体实例中，该方法包括向受试者施用治疗有效量的组合物，其中组合物包含优先结合一种或多种病理性血管发生标志物蛋白的特异性结合剂，包括Vscp，CD276，ETSvg4（Pea3），CD137（4 -1BB），MiRP2，泛素D（Fat10），Doppel（朊病毒-PPL），Apelin，Plgf，Ptprn（IA-2），CD109，强直性和胶原VIIIalpha1。 在另外的实施例中，还公开了将治疗剂递送至脑或肝内皮细胞的方法。